|Day Low/High||5.73 / 5.92|
|52 Wk Low/High||3.42 / 6.31|
NEW YORK, Nov. 08, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc.
Lantheus Holdings, Inc. to Acquire Progenics to Form an Innovative Commercial Life Sciences Company with a Diversified Portfolio of Precision Diagnostics and Radiopharmaceutical Therapeutics AZEDRA Commercial Dosing Progresses in U.
Warns Shareholders to Ignore Earlier and Illusory Consent Cutoff Set by Velan Urges Shareholders to Review the S-4 Filing that Will be Made the Week of November 11 about the Value Maximizing Lantheus Transaction in Order to Make a Fully Informed Final...
November 17 is the Only Deadline for Velan's Consent Solicitation Reminds Shareholders that the S-4 Filing on the Value Maximizing Lantheus Transaction will be Filed with the SEC Before November 17 NEW YORK, Nov.
Notifies Shareholders that the S-4 Filing on the Value Maximizing Lantheus Transaction will be Filed with the SEC Before November 17 Shareholders Should Ignore Any Earlier Dates to Deliver Consents Demanded by Velan Urges Shareholders to Review the S-4...
ISS Recognizes that Shareholders Should Have Full Information About the Lantheus Transaction Before Making Significant Decisions About the Company Progenics Urges Shareholders to Protect the Value of Their Investment by Revoking Consent to ALL of Velan's...
Today, Dr. Gérard Ber released an open letter to stockholders of Progenics Pharmaceuticals, Inc.
In trading on Wednesday, shares of Progenics Pharmaceuticals, Inc. crossed below their 200 day moving average of $4.82, changing hands as low as $4.79 per share.
Flags Velan's Knowledge of Lantheus Transaction Weeks Before It Was Made Public Raises Significant Concerns About Velan's Questionable Securities Trading, Governance and Ethical Practices Asks Velan's Nominees if They Want to Be Associated with These...
Calls Out Velan's Pattern of Disregard for Good Corporate Governance and Business Ethics Reminds Shareholders to Sign and Return Progenics' WHITE Consent Revocation Card NEW YORK, Oct.
Highlights Clear and Compelling Value of Lantheus Transaction to All Shareholders Urges Shareholders to Prevent Velan and its Nominees from Seizing Control of the Board and Company without a Premium to All Shareholders Urges Shareholders to Sign and...
NEW YORK, Oct. 8, 2019 /PRNewswire/ -- Arotech Corporation (ARTX) Lifshitz & Miller announces investigation into possible breach of fiduciary duties in connection with the sale of Arotech to Greenbriar Equity Group, L.
NEW YORK, Oct. 4, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Progenics Pharmaceuticals, Inc.
Former Attorney General of Louisiana Charles C. Foti, Jr.
NEW YORK, Oct. 3, 2019 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating: Chardan Heathcare Acquisition...
MILWAUKEE, Oct. 3, 2019 /PRNewswire/ -- Ademi & O'Reilly, LLP is investigating Progenics (Nasdaq: PGNX) for possible breaches of fiduciary duty and other violations of the law in connection with the sale of Progenics to Lantheus.
NEW YORK, Oct. 2, 2019 /PRNewswire/ -- Bragar Eagel & Squire, P.
NEW YORK, Oct. 2, 2019 /PRNewswire/ -- Rowley Law PLLC is investigating potential claims against Progenics Pharmaceuticals, Inc.
Lantheus will acquire oncology medicine developer Progenics Pharmaceuticals in an all-stock deal.
Lantheus Holdings, Inc. (NASDAQ: LNTH) ("Lantheus"), parent company of Lantheus Medical Imaging, Inc.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.